Therapeutic Area | MeSH |
---|---|
mental disorders | D001523 |
Brand Name | Status | Last Update |
---|---|---|
escitalopram | ANDA | 2024-11-11 |
escitalopram oral solution | ANDA | 2023-09-01 |
escitalopram oxalate | ANDA | 2024-11-07 |
lexapro | New Drug Application | 2023-11-17 |
Expiration | Code | ||
---|---|---|---|
ESCITALOPRAM OXALATE, LEXAPRO, ABBVIE | |||
2026-05-12 | NPP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Depression | D003863 | — | F33.9 | 22 | 58 | 77 | 129 | 105 | 375 |
Depressive disorder | D003866 | EFO_1002014 | F32.A | 25 | 62 | 80 | 129 | 96 | 374 |
Major depressive disorder | D003865 | EFO_0003761 | F22 | 15 | 45 | 53 | 80 | 59 | 244 |
Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 5 | 6 | 12 | 15 | 14 | 49 |
Healthy volunteers/patients | — | — | — | 24 | — | — | 4 | 7 | 35 |
Anxiety | D001007 | EFO_0005230 | F41.1 | — | 1 | 5 | 6 | 7 | 18 |
Syndrome | D013577 | — | — | 2 | 4 | 3 | 6 | 6 | 18 |
Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | — | 1 | 2 | 9 | 5 | 17 |
Compulsive personality disorder | D003193 | — | F60.5 | — | 1 | 2 | 8 | 5 | 16 |
Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 1 | 2 | 4 | 4 | 5 | 15 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 1 | 1 | 4 | — | 2 | 8 |
Cocaine-related disorders | D019970 | — | F14 | 1 | 5 | 1 | — | — | 6 |
Hot flashes | D019584 | — | — | — | — | 1 | — | 4 | 5 |
Parkinson disease | D010300 | EFO_0002508 | G20 | — | 2 | 2 | — | 1 | 4 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | 2 | — | 1 | 4 |
Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | 1 | — | 2 | 3 |
Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | 1 | 1 | — | — | 2 |
Hiv infections | D015658 | EFO_0000764 | B20 | — | — | 2 | — | — | 2 |
Fatigue | D005221 | HP_0012378 | R53.83 | — | 1 | 1 | — | — | 2 |
Myofascial pain syndromes | D009209 | EFO_1001054 | — | — | 2 | 2 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cardiovascular diseases | D002318 | HP_0001626 | — | — | 1 | — | — | 6 | 7 |
Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | — | — | 2 | 3 |
Ischemic stroke | D000083242 | — | — | 1 | 3 | — | — | — | 3 |
Autistic disorder | D001321 | HP_0000717 | F84.0 | 1 | 1 | — | — | 1 | 3 |
Anhedonia | D059445 | — | R45.84 | 1 | 1 | — | — | 2 | 3 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | — | 1 | 2 |
Insulin resistance | D007333 | HP_0000855 | — | — | 1 | — | — | 1 | 2 |
Menopause | D008593 | EFO_0003922 | N95 | — | 1 | — | — | 1 | 2 |
Male infertility | D007248 | EFO_0004248 | N46 | — | 1 | — | — | — | 1 |
Infertility | D007246 | HP_0000789 | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Spinal cord injuries | D013119 | EFO_1001919 | — | 2 | — | — | — | 1 | 3 |
Drug interactions | D004347 | — | — | 1 | — | — | — | 1 | 2 |
Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | 1 | 2 |
Malnutrition | D044342 | EFO_0008572 | E40-E46 | 2 | — | — | — | — | 2 |
Autism spectrum disorder | D000067877 | HP_0000729 | F84.0 | 1 | — | — | — | 1 | 2 |
Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | 2 | — | — | — | — | 2 |
Urinary incontinence | D014549 | HP_0000020 | R32 | 1 | — | — | — | — | 1 |
Stress urinary incontinence | D014550 | HP_0010992 | — | 1 | — | — | — | — | 1 |
Fecal incontinence | D005242 | — | R15 | 1 | — | — | — | — | 1 |
Enuresis | D004775 | — | R32 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 5 | 5 |
Taste disorders | D013651 | — | — | — | — | — | — | 3 | 3 |
Cognition | D003071 | EFO_0003925 | — | — | — | — | — | 3 | 3 |
Pharmacokinetics | D010599 | — | — | — | — | — | — | 2 | 2 |
Disease | D004194 | EFO_0000408 | R69 | — | — | — | — | 2 | 2 |
Adolescent development | D041923 | — | — | — | — | — | — | 2 | 2 |
Affective symptoms | D000342 | — | — | — | — | — | — | 2 | 2 |
Perimenopause | D047648 | — | — | — | — | — | — | 1 | 1 |
Chronic pain | D059350 | HP_0012532 | — | — | — | — | — | 1 | 1 |
Intractable pain | D010148 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Escitalopram |
INN | escitalopram |
Description | Escitalopram is a 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile that has S-configuration at the chiral centre. It is the active enantiomer of citalopram. It has a role as an antidepressant and an EC 3.4.21.26 (prolyl oligopeptidase) inhibitor. It is a conjugate base of an escitalopram(1+). It is an enantiomer of a (R)-citalopram. |
Classification | Small molecule |
Drug class | Selective serotonin reuptake inhibitor (SSRI) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21 |
PDB | — |
CAS-ID | 128196-01-0 |
RxCUI | — |
ChEMBL ID | CHEMBL1508 |
ChEBI ID | 36791 |
PubChem CID | 146570 |
DrugBank | DB01175 |
UNII ID | 4O4S742ANY (ChemIDplus, GSRS) |